Analysis of Cellular Immune Response after SARS-CoV-2 Vaccination as An Alternative for Evaluation of Vaccination Success Khariri (1,2), Telly Purnamasari Agus (2*), Tonang Dwi Ardyanto (3), Amin Subandrio (4)
1) Doctoral Program of Biomedical Science, Faculty of Medicine, Indonesia University, Indonesia
2) National Research and Innovation Agency, Indonesia
3) Clinical Pathology Department, Faculty of Medicine, Sebelas Maret University, Indonesia
4) Clinical Microbiology Department, Faculty of Medicine, Indonesia University, Indonesia
*Corresponding author: telly2pramadi
Abstract
Coronavirus Disease (Covid-19) was first discovered in December 2019 in Wuhan and has spread to almost all countries, making it an international health problem. On March 11, 2020, the World Health Organization (WHO) declared Covid-19 as a pandemic. In Indonesia, the first case was announced to the public on March 2, 2020. So far, there is no effective treatment for Covid-19 patients. One of the efforts to prevent Covid-19 infection can be done by vaccination. With vaccination, the body is trained to form an immune response to infection by introducing specific substances that can be recognized by the body. The Covid-19 vaccination needs to be given repeatedly because the humoral immune response only lasts a short time. Adaptive immunity to the longer-lasting Covid-19 vaccine is cellularly mediated by memory T cells. With the prediction that antibody titers will decrease with time since vaccination, an appropriate vaccine administration strategy is needed and the vaccination rate continues to increase in order to achieve this target. Time is a very important factor when using antibody titers as a guide in developing a vaccination program. The analysis is an interesting thing to do to see whether T cells produced from vaccination can also provide longer adaptive immunity against viral infections so that they can be used as an alternative to evaluate the success of vaccination.
